[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614942":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":60,"centralContacts":64,"locations":70,"responsibleParty":359,"collaborators":361,"id":364,"slug":32,"hasResults":365,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":32,"eligibilityCriteria":369,"healthyVolunteers":365,"sex":370,"minAge":371,"maxAge":32,"enrollmentInfo":372,"targetDuration":32,"studyType":375,"phases":376,"briefSummary":379,"conditions":380,"keywords":32,"overallStatus":73,"whyStopped":32,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":391},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,15,21],{"label":9,"type":10,"description":11,"interventionNames":12},"MK-1084 + Patritumab deruxtecan (HER3-DXd)","EXPERIMENTAL","Participants will receive MK-1084 and HER3-DXd until discontinuation due to toxicity, adverse event (AE) or at the discretion of an investigator.",[13,14],"Drug: MK-1084","Biological: Patritumab deruxtecan",{"label":16,"type":10,"description":17,"interventionNames":18},"MK-1084 + Sacituzumab tirumotecan (Sac-TMT)","Participants will receive MK-1084 and sac-TMT until discontinuation due to toxicity, AE or at the discretion of an investigator.",[13,19,20],"Biological: Sacituzumab tirumotecan","Drug: Rescue Medications",{"label":22,"type":10,"description":23,"interventionNames":24},"MK-1084 + Cetuximab","Participants will receive MK-1084 and cetuximab until discontinuation due to toxicity, AE or at the discretion of an investigator.",[13,25],"Biological: Cetuximab",[27,33,42,50,56],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","MK-1084","Oral administration",[22,9,16],null,{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"BIOLOGICAL","Patritumab deruxtecan","IV infusion",[9],[39,40,41],"HER3-DXd","MK-1022","U3-1402",{"type":34,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"Sacituzumab tirumotecan","IV Infusion",[16],[47,48,49],"Sac-TMT","MK-2870","SKB264",{"type":34,"name":51,"description":44,"armGroupLabels":52,"otherNames":53},"Cetuximab",[22],[54,55],"C225","Erbitux",{"type":28,"name":57,"description":58,"armGroupLabels":59,"otherNames":32},"Rescue Medications","Participants receive rescue medication at the investigator's discretion, per approved product label. Recommended rescue medications are histamine -1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent) for prevention of chemotherapy induced nausea and vomiting.",[16],[61],{"name":62,"affiliation":5,"role":63},"Medical Director","STUDY_DIRECTOR",[65],{"name":66,"role":67,"phone":68,"phoneExt":32,"email":69},"Toll Free Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[71,88,101,114,122,136,149,161,172,186,195,204,218,232,241,253,264,275,288,300,314,327,336,347],{"facility":72,"status":73,"city":74,"state":75,"zip":76,"country":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":84},"Clermont Oncology Center ( Site 0041)","RECRUITING","Clermont","Florida","34711","United States",{"type":79,"coordinates":80},"Point",[81,82],-81.77285,28.54944,{"lat":82,"lon":81},[85],{"name":86,"role":67,"phone":87,"phoneExt":32,"email":32},"Study Coordinator","386-538-3169",{"facility":89,"status":73,"city":90,"state":91,"zip":92,"country":77,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"University of Illinois Hospital & Health Sciences System ( Site 0044)","Chicago","Illinois","60612",{"type":79,"coordinates":94},[95,96],-87.65005,41.85003,{"lat":96,"lon":95},[99],{"name":86,"role":67,"phone":100,"phoneExt":32,"email":32},"312-996-9272",{"facility":102,"status":73,"city":103,"state":104,"zip":105,"country":77,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Providence Portland Medical Center ( Site 0043)","Portland","Oregon","97213",{"type":79,"coordinates":107},[108,109],-122.67621,45.52345,{"lat":109,"lon":108},[112],{"name":86,"role":67,"phone":113,"phoneExt":32,"email":32},"503-215-1979",{"facility":115,"status":73,"city":103,"state":104,"zip":116,"country":77,"cosmosGeoPoint":117,"geoPoint":119,"contacts":120},"Providence Oncology and Hematology Care Clinic - Westside ( Site 0059)","97225",{"type":79,"coordinates":118},[108,109],{"lat":109,"lon":108},[121],{"name":86,"role":67,"phone":113,"phoneExt":32,"email":32},{"facility":123,"status":73,"city":124,"state":125,"zip":126,"country":127,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Hospital São Lucas da PUCRS ( Site 0283)","Porto Alegre","Rio Grande do Sul","90610-000","Brazil",{"type":79,"coordinates":129},[130,131],-51.23019,-30.03283,{"lat":131,"lon":130},[134],{"name":86,"role":67,"phone":135,"phoneExt":32,"email":32},"+555133203000",{"facility":137,"status":73,"city":138,"state":139,"zip":140,"country":127,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0282)","Barretos","São Paulo","14784-400",{"type":79,"coordinates":142},[143,144],-48.56778,-20.55722,{"lat":144,"lon":143},[147],{"name":86,"role":67,"phone":148,"phoneExt":32,"email":32},"+551733216637",{"facility":150,"status":73,"city":151,"state":139,"zip":152,"country":127,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0286)","São José do Rio Preto","15090-000",{"type":79,"coordinates":154},[155,156],-49.37944,-20.81972,{"lat":156,"lon":155},[159],{"name":86,"role":67,"phone":160,"phoneExt":32,"email":32},"+551732015000",{"facility":162,"status":73,"city":139,"state":139,"zip":163,"country":127,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"Hospital Paulistano ( Site 0280)","01321001",{"type":79,"coordinates":165},[166,167],-46.63611,-23.5475,{"lat":167,"lon":166},[170],{"name":86,"role":67,"phone":171,"phoneExt":32,"email":32},"55 11 31411083",{"facility":173,"status":73,"city":174,"state":175,"zip":176,"country":177,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0162)","Santiago","Region M. de Santiago","7500653","Chile",{"type":79,"coordinates":179},[180,181],-70.64827,-33.45694,{"lat":181,"lon":180},[184],{"name":86,"role":67,"phone":185,"phoneExt":32,"email":32},"+56991612199",{"facility":187,"status":73,"city":174,"state":175,"zip":188,"country":177,"cosmosGeoPoint":189,"geoPoint":191,"contacts":192},"FALP ( Site 0161)","7500921",{"type":79,"coordinates":190},[180,181],{"lat":181,"lon":180},[193],{"name":86,"role":67,"phone":194,"phoneExt":32,"email":32},"56229490970",{"facility":196,"status":73,"city":174,"state":175,"zip":197,"country":177,"cosmosGeoPoint":198,"geoPoint":200,"contacts":201},"Bradfordhill ( Site 0160)","8420383",{"type":79,"coordinates":199},[180,181],{"lat":181,"lon":180},[202],{"name":86,"role":67,"phone":203,"phoneExt":32,"email":32},"+56229490970",{"facility":205,"status":73,"city":206,"state":207,"zip":208,"country":209,"cosmosGeoPoint":210,"geoPoint":214,"contacts":215},"Guangdong Provincial People s Hospital ( Site 0300)","Guangzhou","Guangdong","510120","China",{"type":79,"coordinates":211},[212,213],113.25,23.11667,{"lat":213,"lon":212},[216],{"name":86,"role":67,"phone":217,"phoneExt":32,"email":32},"02083525210",{"facility":219,"status":73,"city":220,"state":221,"zip":222,"country":223,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"THORACIC GENERAL HOSPITAL OF ATHENS \"I SOTIRIA\" ( Site 0204)","Athens","Attica","115 27","Greece",{"type":79,"coordinates":225},[226,227],23.72784,37.98376,{"lat":227,"lon":226},[230],{"name":86,"role":67,"phone":231,"phoneExt":32,"email":32},"+30210 7763100",{"facility":233,"status":73,"city":220,"state":221,"zip":234,"country":223,"cosmosGeoPoint":235,"geoPoint":237,"contacts":238},"Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 0205)","115 28",{"type":79,"coordinates":236},[226,227],{"lat":227,"lon":226},[239],{"name":86,"role":67,"phone":240,"phoneExt":32,"email":32},"+302132162543",{"facility":242,"status":73,"city":243,"state":32,"zip":244,"country":243,"cosmosGeoPoint":245,"geoPoint":249,"contacts":250},"Queen Mary Hospital ( Site 0230)","Hong Kong","000000",{"type":79,"coordinates":246},[247,248],114.17469,22.27832,{"lat":248,"lon":247},[251],{"name":86,"role":67,"phone":252,"phoneExt":32,"email":32},"+85222551727",{"facility":254,"status":73,"city":255,"state":32,"zip":244,"country":243,"cosmosGeoPoint":256,"geoPoint":260,"contacts":261},"Hong Kong United Oncology Centre ( Site 0232)","Jordan",{"type":79,"coordinates":257},[258,259],114.17001,22.30539,{"lat":259,"lon":258},[262],{"name":86,"role":67,"phone":263,"phoneExt":32,"email":32},"+852 5508 7858",{"facility":265,"status":73,"city":266,"state":32,"zip":32,"country":243,"cosmosGeoPoint":267,"geoPoint":271,"contacts":272},"Prince of Wales Hospital ( Site 0231)","Shatin",{"type":79,"coordinates":268},[269,270],114.18333,22.38333,{"lat":270,"lon":269},[273],{"name":86,"role":67,"phone":274,"phoneExt":32,"email":32},"+852 3505 1202",{"facility":276,"status":73,"city":277,"state":32,"zip":278,"country":279,"cosmosGeoPoint":280,"geoPoint":284,"contacts":285},"Shaare Zedek Medical Center ( Site 0186)","Jerusalem","9103102","Israel",{"type":79,"coordinates":281},[282,283],35.21633,31.76904,{"lat":283,"lon":282},[286],{"name":86,"role":67,"phone":287,"phoneExt":32,"email":32},"+97226555999",{"facility":289,"status":73,"city":290,"state":32,"zip":291,"country":279,"cosmosGeoPoint":292,"geoPoint":296,"contacts":297},"Sheba Medical Center ( Site 0180)","Ramat Gan","5265601",{"type":79,"coordinates":293},[294,295],34.81065,32.08227,{"lat":295,"lon":294},[298],{"name":86,"role":67,"phone":299,"phoneExt":32,"email":32},"+97235303030",{"facility":301,"status":73,"city":302,"state":303,"zip":304,"country":305,"cosmosGeoPoint":306,"geoPoint":310,"contacts":311},"IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\" ( Site 0176)","Meldola","Forli-Cesena","47014","Italy",{"type":79,"coordinates":307},[308,309],12.0626,44.12775,{"lat":309,"lon":308},[312],{"name":86,"role":67,"phone":313,"phoneExt":32,"email":32},"393487469100",{"facility":315,"status":73,"city":316,"state":32,"zip":317,"country":318,"cosmosGeoPoint":319,"geoPoint":323,"contacts":324},"Severance Hospital, Yonsei University Health System ( Site 0080)","Seoul","03722","South Korea",{"type":79,"coordinates":320},[321,322],126.9784,37.566,{"lat":322,"lon":321},[325],{"name":86,"role":67,"phone":326,"phoneExt":32,"email":32},"+82222280880",{"facility":328,"status":73,"city":329,"state":330,"zip":331,"country":332,"cosmosGeoPoint":32,"geoPoint":32,"contacts":333},"Institut Català d'Oncologia - L'Hospitalet ( Site 0090)","Hospitalet","Barcelona","08908","Spain",[334],{"name":86,"role":67,"phone":335,"phoneExt":32,"email":32},"0034932607744",{"facility":337,"status":73,"city":330,"state":32,"zip":338,"country":332,"cosmosGeoPoint":339,"geoPoint":343,"contacts":344},"Hospital Clinic de Barcelona ( Site 0092)","08036",{"type":79,"coordinates":340},[341,342],2.15899,41.38879,{"lat":342,"lon":341},[345],{"name":86,"role":67,"phone":346,"phoneExt":32,"email":32},"34 932275402",{"facility":348,"status":73,"city":349,"state":32,"zip":350,"country":332,"cosmosGeoPoint":351,"geoPoint":355,"contacts":356},"Hospital Universitario Virgen Macarena ( Site 0093)","Seville","41009",{"type":79,"coordinates":352},[353,354],-5.97317,37.38283,{"lat":354,"lon":353},[357],{"name":86,"role":67,"phone":358,"phoneExt":32,"email":32},"+34 671560092",{"type":360,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[362],{"name":363,"class":6},"Daiichi Sankyo","100614942",false,"NCT07286149","A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","KEYMAKER-U01 Substudy 01F: A Phase 1b\u002F2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)\n* Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene (KRAS) mutation of glycine to cysteine at codon 12 (G12C) mutations\n* Has documented disease progression after receiving 1-2 prior lines of programmed cell death protein 1 (PD-1)\u002Fprogrammed death-ligand 1 (PD-L1) therapy and platinum-based chemotherapy\n* Provides archival tumor tissue sample of a tumor lesion not previously irradiated\n* Has provided tissue prior to treatment allocation\u002Frandomization from a newly obtained biopsy of a tumor lesion not previously irradiated\n* Participants with human immunodeficiency virus (HIV) infection must have well-controlled HIV on antiretroviral therapy (ART) per protocol\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements\n* Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease\n* Has evidence of any leptomeningeal disease\n* Has uncontrolled or significant cardiovascular disorder or cerebrovascular disease prior to allocation\u002Frandomization\n* Has one or more of the following ophthalmological conditions: a) Clinically significant corneal disease b) history of documented severe dry eye syndrome, severe Meibomian gland disease and\u002For blepharitis\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Has received previous treatment with an agent targeting KRAS\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention\n* Has known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has history of (noninfectious) pneumonitis\u002F interstitial lung disease (ILD) that required steroids or has current pneumonitis\u002FILD\n* Has an active infection requiring systemic therapy\n* Have not adequately recovered from major surgery or have ongoing surgical complications","ALL","18 Years",{"count":373,"type":374},190,"ESTIMATED","INTERVENTIONAL",[377,378],"PHASE1","PHASE2","Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn:\n\n* About the safety of MK-1084 and if people tolerate it when taken with other treatments\n* How many people have the cancer respond (get smaller or go away) to the treatments",[381],"Lung Neoplasm Malignant","2026-06-16",{"date":384,"type":385},"2026-06-18","ACTUAL",{"date":387,"type":385},"2026-04-30",{"date":389,"type":374},"2032-04-13",{"name":5,"class":6},24]